Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors

NCT07566897 is registered in ClinicalTrials.gov with Philogen S.p.A. as lead sponsor.

NCT NCT07566897
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07566897 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors
Lead sponsor
Philogen S.p.A.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
May 1, 2026
Completion date
May 31, 2030
Enrollment
96 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal carcinoma (mcrc), pancreatic adenocarcinoma, pancreatic adenocarcinoma metastatic, renal carcinoma metastatic